Abstract
Synergy between yttrium-90 (90Y) and antineoplastic drugs was investigated. Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay. A combination index (CI) was calculated, with CI < 1 denoting synergy and CI > 1 denoting antagonism. In HepaRG cells, gemcitabine showed synergy with 90Y (CI = 0.70 [95% confidence interval = 0.65–0.75]), whereas oxaliplatin (CI = 1.15 [1.08–1.21]), paclitaxel (CI = 1.26 [1.15–1.37]), and sorafenib (CI = 1.77 [1.65–1.89]) showed antagonism. In HuCCT1 cells, gemcitabine (CI = 0.54 [0.50–0.58]) and oxaliplatin (CI = 0.86 [0.82–0.90]) showed synergy with 90Y, whereas paclitaxel (CI = 1.18 [1.09–1.27]) and sorafenib (CI = 1.21 [1.12–1.30]) showed antagonism. These results suggest that gemcitabine and oxaliplatin should be tested in combination with 90Y radioembolization for treatment of liver cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
